Canadian CANNAINVESTOR Magazine June / July 2018 | Page 70

70

Weedman character was created and is the sole property of and owned by Chloë Kyron. All rights reserved. The image including any likeness cannot be used in any manner without the expressed written consent by Chloë Kyron.

Any company referenced is purely for discussion purposes and not intended as a recommendation.

Louis Kyron, CPA, CGA

We know that they have targeted brand diversification and we will be discussing in the Q&A their international diversification and markets. Organigram is also investing in technology that has the potential to revolutionize the industry. Do you think I am exaggerating or playing this up with such a bold statement? We know that 22nd Century Corp (N:XXII) is developing technology whereby “Its researchers are creating so-called enabling tools that expedite the targeted bioengineering of cannabinoid production in the cannabis plant, with the goal of creating new strains of cannabinoids for new drug treatments and agricultural applications” (source). Well Organigram has entered into a Letter of Intent (LOI) with respect to a strategic investment in Montreal’s Hyasynth Biologicals Inc (Hyasynth) (click here for the news release). Hyasynth is developing technology that will allow the extraction of CBG, THCA, and CBD from engineered strains of yeast. For more information on their patent-pending technology to produce phytocannabinoids from these engineered strains of yeast please visit their website by clicking here. For a great video on Hyansynth (pronounced “Hi-A-Synth”) just click here (have Facebook open and yourself logged in when launching).

Whether in my monthly articles appearing in the Canadian and US editions, or when I am a guest speaker or a panelist … I emphasize a key to success in this industry is to be able to imagine! Yes – Imagine. Maybe not having superpowers but the ability to imagine the possibilities of the future. Imagine what cannabis will do for the world whether it be in health, animal care, food and nutrition, textiles, building materials, plastics and other substitutes, etc. Imagine when science can definitively prove cannabis as an effective treatment for just one medical condition. Now imagine two … now three … now four. Organigram is a success. Organigram is forward thinking. They are entrepreneurial and visionary. They have imagination and they know what this technology would mean to R&D as well as to commercial and consumer applications. Imagine being able to create targeted levels of THC and CBD in days not weeks or months and without the space and cost/resource requirements of traditional growing. The LOI at time of writing is non-binding as it subject to further due diligence and other procedural matters before it advances, but it demonstrates that OGI has the will to be at the forefront of game-changing technology that could transform the industry.

Louis Kyron and Ray Gracewood, CCO of Organigram, at O’Cannabiz on June 8th in Toronto Ontario.